Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromfenac sodium + prednisolone acetate is a combination ophthalmic medication used primarily for the treatment of postoperative inflammation and pain following cataract surgery. This combination leverages the complementary mechanisms of both active ingredients: - **Prednisolone acetate** is a synthetic corticosteroid that reduces inflammation by suppressing various inflammatory mediators - **Bromfenac sodium** is a nonsteroidal anti-inflammatory agent (NSAID) that inhibits prostaglandin synthesis The medication is typically formulated as an ophthalmic suspension/solution for topical application to the eye.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromfenac sodium + prednisolone acetate.